Biotin (Vitamin B7)
Of 9,522 on-market biotin (vitamin b7) products in the January 2026 DSLD dump, the median declared dose is 150 mcg, and 100.0% list D-Biotin as the primary form.
Form share
Of 9,468 products with an identifiable primary form, here is the share held by each form of Biotin (Vitamin B7) on the market today.
| Form | Quality tier | n | Share |
|---|---|---|---|
| D-Biotin | Tier 1 | 9,468 | 100.0% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mcg), among 9,316 products with a disclosed amount, against the RDA of 30.
- 99.4% of products fall below the fairy-dust threshold (20000 mcg, 20% of the studied low dose).
- 0.3% of products don't disclose an amount because Biotin (Vitamin B7) is declared inside a proprietary blend.
By dosage form
By target group
Top brands
Forms explained
D-biotin is the only one of biotin's eight possible stereoisomers with vitamin activity, both the naturally occurring form in food and the form targeted by commercial synthesis (per USP monograph) -- bare "Biotin" (the largest raw_form bucket, ~15,405 rows) is treated as the same molecule.
Source: General biochemistry consensus on biotin stereochemistry; no comparative study needed since other stereoisomers aren't marketed as vitamins
Not a distinct chemical form -- a whole-food matrix/carrier ingredient, not a different biotin vitamer.
Reference values
- RDA (adult): 30 mcg — Adequate Intake, no RDA established: 30mcg/day for adults (values extrapolated from infant data)
- Tolerable Upper Intake Level (adult): not established — Confirmed not established (not merely assumed) -- no evidence of biotin toxicity in humans; studies of 10-50mg/day found no adverse effects, up to 200mg/day oral produced no toxicity signs. Separately, high-dose biotin supplementation is documented to cause clinically significant false lab results (e.g. troponin, thyroid panels) via immunoassay interference -- a real safety concern, but distinct from a toxicological UL.
- Studied clinical dose range: 100000–300000 mcg
- Tourbah A et al. 2016 (MS-SPI study), Mult Scler 22(13):1719-1731, PMID 27589059 -- RCT (n=154), MD1003 (biotin 300mg/day = 300,000mcg) produced disability improvement in 12.6% of treated progressive-MS patients vs 0% placebo (p=0.0051) at 9-12 months. NOTE: a larger phase 3 follow-up (SPI2, Lancet Neurol 2020) did NOT confirm significance on the primary endpoint -- the positive MS-SPI result was not replicated.
- Note: studied_dose values are from a pharmacologic MS trial, not typical consumer hair/ nail dosing (2.5-10mg/day) -- no verifiable primary citation was found at that lower dose range this session, so it isn't represented here. "D-Biotin" and bare "Biotin" (the largest raw_form bucket in DSLD, ~15,405 rows) are treated as the same molecule -- D-biotin is the only industrially synthesized, vitamin-active stereoisomer.